Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ESTRONE vs ANDROID-F
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estrone is a natural estrogen that binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and exerting estrogenic effects on reproductive, skeletal, and cardiovascular systems.
Fingolimod is a sphingosine 1-phosphate receptor modulator that sequesters lymphocytes in lymph nodes, reducing central nervous system immune cell infiltration.
Moderate to severe vasomotor symptoms associated with menopause,Vulvar and vaginal atrophy,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prevention of postmenopausal osteoporosis (off-label in some contexts),Prostate cancer (palliative therapy, off-label),Breast cancer (palliative therapy in selected cases, off-label)
Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
For menopausal hormone therapy: 0.625-5 mg orally once daily; or 0.1-0.5 mg transdermally once weekly; or 2.5-5 mg intramuscularly every 2-4 weeks.
Adults: 1 tablet (methyltestosterone 2.5 mg, ethinyl estradiol 0.025 mg) orally once daily, with food.
Terminal elimination half-life is 24-36 hours; due to enterohepatic recirculation and slow clearance of conjugates, clinical effects persist for several days after discontinuation.
2.5-3.5 hours (terminal half-life); oral administration may require multiple daily doses for stable levels.
Metabolized primarily in the liver via hydroxylation by cytochrome P450 enzymes (CYP3A4, CYP1A2, CYP2C9, CYP2C19) and conjugation to glucuronides and sulfates. Estrone is interconvertible with estradiol and estriol. Enterohepatic recirculation occurs.
Metabolized primarily by CYP4F2, with minor contributions from CYP2D6, CYP2E1, CYP3A4, and CYP1A2. Undergoes biotransformation to an inactive metabolite.
Renal (approximately 60-80% as glucuronide and sulfate conjugates), biliary/fecal (20-40%)
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); small amount biliary/fecal.
Approximately 96-98% bound to albumin and sex hormone-binding globulin (SHBG)
97-99% bound to sex hormone-binding globulin (SHBG) and albumin.
0.8-1.2 L/kg; indicates extensive distribution into tissues, particularly adipose tissue.
0.5-0.8 L/kg; reflects distribution into muscle, liver, and reproductive tissues.
Oral: ~5% due to extensive first-pass metabolism; Intramuscular: 100%; Topical: variable, approximately 10% systemically.
Oral: 3-6% (extensive first-pass metabolism); IM: 100%.
No specific dose adjustments provided; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of metabolites; monitor estrogenic effects.
GFR 10-50 m L/min: reduce dose by 50%. GFR <10 m L/min: avoid use.
Contraindicated in severe hepatic impairment (Child-Pugh class C). In Child-Pugh class A or B, reduce dose by 50% and monitor liver function; start at lowest effective dose.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: avoid use. Child-Pugh C: contraindicated.
Not indicated for routine use; individualize for rare conditions (e.g., delayed puberty) under specialist guidance. Typical starting dose: 0.3-0.625 mg orally once daily; adjust based on response and bone age.
Not recommended for use in children due to risk of premature epiphyseal closure and virilization.
Start at low end of dosing range (e.g., 0.3-0.625 mg orally once daily); consider increased risk of thromboembolism and endometrial cancer; monitor for adverse effects; use shortest duration possible.
Use with caution; consider lower starting dose due to increased risk of fluid retention, hypertension, and prostatic hypertrophy in males.
Estrogens increase the risk of endometrial cancer in postmenopausal women. Unopposed estrogen use is associated with increased risk of endometrial hyperplasia and carcinoma. Adequate diagnostic measures should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding.
Risk of bradyarrhythmia and atrioventricular block, requiring first-dose monitoring for 6 hours. Fatal infections, including opportunistic infections, have occurred. Macular edema has been reported.
Cardiovascular disorders: Increased risk of stroke, DVT, pulmonary embolism, and myocardial infarction, especially in smokers and older women,Malignancy: Increased risk of endometrial cancer (unopposed estrogen) and potential for breast cancer; avoid use in known or suspected estrogen-dependent neoplasia,Dementia: Possible increased risk in women over 65 years,Gallbladder disease: Increased risk of cholelithiasis,Hypertriglyceridemia: May cause severe hypertriglyceridemia with pancreatitis,Hepatic impairment: Use with caution; may be contraindicated in severe disease,Fluid retention: May exacerbate conditions such as asthma, epilepsy, migraine, cardiac or renal dysfunction,Hypocalcemia: Should be used with caution in patients with hypoparathyroidism,Visual abnormalities: Discontinue if sudden vision loss, proptosis, or migraine develops
May cause bradycardia and AV block; monitor heart rate after first dose. Increased risk of infections, including herpes viruses and cryptococcal meningitis. Macular edema, especially in patients with diabetes or uveitis. Posterior reversible encephalopathy syndrome (PRES). Respiratory effects, including decreased FEV1 and DLCO. Hepatic injury; monitor liver enzymes.
Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Known or suspected breast cancer (except in selected palliative cases),Known or suspected estrogen-dependent neoplasia,Active or history of venous thromboembolism (e.g., DVT, pulmonary embolism),Active arterial thromboembolic disease (e.g., stroke, MI),Severe hepatic impairment or disease,Hypersensitivity to estrone or any component of the formulation
Recent myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure, history of Mobitz type II 2nd or 3rd degree AV block, sick sinus syndrome unless pacemaker is present, or severe untreated sleep apnea.
Grapefruit and grapefruit juice may inhibit estrone metabolism, increasing serum levels and risk of adverse effects. Avoid concomitant high-fat meals as they may alter absorption. No other significant food interactions reported. Maintain adequate calcium and vitamin D intake for bone health.
No significant food interactions reported. Avoid excessive alcohol consumption due to hepatotoxic effects.
First trimester: Theoretical risk of fetal harm based on estrogenic effects, but no well-controlled studies. Second and third trimesters: Avoid use due to risk of fetal genital tract abnormalities and potential for other adverse effects. Overall: FDA Pregnancy Category X (contraindicated) unless used for specific conditions like progesterone-resistant recurrent pregnancy loss.
ANDROID-F contains methyltestosterone, a synthetic androgen. Androgens are teratogenic in humans. In first trimester: masculinization of female fetus, including clitoromegaly, labial fusion, and urogenital sinus abnormalities. Second and third trimesters: continued virilization of female fetus; no increased risk of malformations in male fetuses. Contraindicated in pregnancy.
Estrone is excreted in human breast milk; M/P ratio not determined. Use during lactation is generally contraindicated as estrogens may suppress milk production and alter milk composition. Alternative agents recommended if breastfeeding.
Methyltestosterone is excreted in breast milk. No specific M/P ratio available. May cause virilization in female infants and precocious development in male infants. Breastfeeding is contraindicated during therapy.
No recommended dosing in pregnancy due to contraindication; if used, no established dose adjustments exist. Estrogen clearance is increased in pregnancy, but systematic data for estrone are lacking; generally, avoidance is advised.
ANDROID-F is contraindicated in pregnancy; no dosing recommendations for use in pregnancy. No established dose adjustments exist as the drug should not be administered.
Estrone is primarily used in menopausal hormone therapy and has weak estrogenic activity compared to estradiol. Monitor for endometrial hyperplasia in women with an intact uterus; concurrent progestin is required. Assess thromboembolic risk before initiation. Estrone may be less effective for vasomotor symptoms than estradiol. Avoid in patients with breast cancer, liver disease, or undiagnosed vaginal bleeding.
Android-F is a brand of methyltestosterone, an androgen used primarily for male hypogonadism. Monitor liver function due to potential hepatotoxicity. Avoid in males with breast or prostate cancer. Use with caution in older patients due to increased risk of prostatic hypertrophy. May suppress clotting factors II, V, VII, and X.
Take estrone exactly as prescribed; do not alter dose or frequency.,Report any unusual vaginal bleeding, breast lumps, or jaundice immediately.,Estrone does not protect against HIV or other sexually transmitted infections.,You may experience nausea, headache, or breast tenderness; contact your doctor if severe.,Do not use estrone if you are pregnant, think you might be pregnant, or are breastfeeding.,Avoid smoking and excessive alcohol consumption to reduce cardiovascular risks.
Take exactly as prescribed; do not increase dose or frequency.,Report any signs of liver problems (yellowing eyes/skin, dark urine, persistent nausea) immediately.,Women should report hoarseness, acne, or menstrual changes.,Men should report frequent or persistent erections, or breast swelling/tenderness.,May cause decreased sperm count in men; discuss family planning.,Avoid concurrent use with other medications without consulting doctor.
"Almasilate, a magnesium-aluminum antacid, can adsorb estrone in the gastrointestinal tract, reducing its absorption and systemic bioavailability. This interaction may lead to subtherapeutic estrone levels, potentially diminishing its therapeutic effects in hormone replacement therapy. Patients may experience inadequate symptom control or hormonal imbalance if the drugs are taken concomitantly without proper timing separation."
"Clarithromycin is a potent CYP3A4 inhibitor and also inhibits P-glycoprotein, significantly decreasing the clearance of estrone, which is metabolized via CYP3A4 and transported by P-gp. This leads to elevated estrone plasma concentrations, increasing estrogenic effects such as thromboembolic risk, breast tenderness, and endometrial proliferation. Clinical vigilance is warranted, especially in patients on hormone replacement therapy or using estrone for menopausal symptoms, as coadministration may precipitate estrogen-related adverse events."
"Estrone, an estrogen hormone, may induce the expression of UDP-glucuronosyltransferase (UGT) enzymes, which are involved in the glucuronidation and subsequent clearance of afatinib. This induction can lead to a decrease in afatinib serum concentrations, potentially reducing its efficacy in the treatment of non-small cell lung cancer. Clinically, this interaction may result in suboptimal therapeutic outcomes unless the afatinib dose is adjusted."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ESTRONE vs ANDROID-F, answered by our medical review team.
ESTRONE is a Estrogen that works by Estrone is a natural estrogen that binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and exerting estrogenic effects on reproductive, skeletal, and cardiovascular systems.. ANDROID-F is a Androgen/Estrogen Combination that works by Fingolimod is a sphingosine 1-phosphate receptor modulator that sequesters lymphocytes in lymph nodes, reducing central nervous system immune cell infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ESTRONE and ANDROID-F depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ESTRONE is: For menopausal hormone therapy: 0.625-5 mg orally once daily; or 0.1-0.5 mg transdermally once weekly; or 2.5-5 mg intramuscularly every 2-4 weeks.. The standard adult dose of ANDROID-F is: Adults: 1 tablet (methyltestosterone 2.5 mg, ethinyl estradiol 0.025 mg) orally once daily, with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ESTRONE and ANDROID-F in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ESTRONE is classified as Category C. First trimester: Theoretical risk of fetal harm based on estrogenic effects, but no well-controlled studies. Second and third trimesters: Avoid use due to risk of fetal genital tra. ANDROID-F is classified as Category C. ANDROID-F contains methyltestosterone, a synthetic androgen. Androgens are teratogenic in humans. In first trimester: masculinization of female fetus, including clitoromegaly, labi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.